The group's principal activity is to research, produce and deliver peptides for medical use. The group has developed manufacturing technology for producing peptides cost-effectively. It has also patented oral and nasal delivery technology that has been shown to deliver medically useful amounts of various peptides into the bloodstream. The initial products of the group will be injectable, nasal and oral formulations of calcitonin for the treatment of osteoporosis and other indications. The group has also developed novel drug delivery technology that delivers therapeutic levels of the amidated peptide calcitonin into the bloodstream.
